Prospective single-centre study investigating the single nucleotide polymorphisms (SNPs) occurring in patients with metastatic breast cancer treated with Everolimus (EVE) and Exemestane (EXE)

Trial Profile

Prospective single-centre study investigating the single nucleotide polymorphisms (SNPs) occurring in patients with metastatic breast cancer treated with Everolimus (EVE) and Exemestane (EXE)

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2016

At a glance

  • Drugs Everolimus (Primary) ; Exemestane (Primary)
  • Indications Advanced breast cancer
  • Focus Pharmacogenomic; Pharmacokinetics
  • Most Recent Events

    • 09 Feb 2016 New trial record
    • 12 Dec 2015 Results presented at the 38th Annual San Antonio Breast Cancer Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top